Last reviewed · How we verify
Candicort®
Candicort is a topical corticosteroid that reduces inflammation and suppresses immune responses in affected skin areas.
Candicort is a topical corticosteroid that reduces inflammation and suppresses immune responses in affected skin areas. Used for Inflammatory and pruritic dermatological conditions (e.g., eczema, dermatitis, psoriasis).
At a glance
| Generic name | Candicort® |
|---|---|
| Also known as | ketoconazole and betamethasone dipropionate |
| Sponsor | Ache Laboratorios Farmaceuticos S.A. |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a corticosteroid, Candicort works by binding to glucocorticoid receptors in inflammatory cells, leading to decreased production of inflammatory mediators and reduced vasodilation. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects on the skin. The drug is applied topically to localized dermatological conditions.
Approved indications
- Inflammatory and pruritic dermatological conditions (e.g., eczema, dermatitis, psoriasis)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation
Key clinical trials
- Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candicort® CI brief — competitive landscape report
- Candicort® updates RSS · CI watch RSS
- Ache Laboratorios Farmaceuticos S.A. portfolio CI